Kidney Week

John P. Peters Award, Homer W. Smith Award, Donald W. Seldin Young Investigator Award and Address, State-of-the-Art Lecture Note: Continuing education credits are not being offered for this session.

Poster sessions will be posted on October 2. Note: Continuing education credits are not being offered for these sessions.

Exhibitor Spotlights (10:15-1:45)

This session highlights the complexities of the genetic basis of kidney diseases. Presentations feature cutting-edge research on the genetics of complex kidney traits and showcase a diverse range of approaches and insights emerging from large biobank-scale genetic analyses.

Pediatric CKD is shaped not only by biology, but also by lived experience, social context, nutrition, and preventive care. This session centers the voices of patients and families while integrating emerging evidence on social drivers of disease progression, advances in pediatric CKD nutrition, and challenges such as vaccine hesitan...

CKRT is the preferred modality of kidney replacement therapy for critically ill patients with AKI. Because solutes and proteins up to 30 kDa may be removed during CKRT, important and unexpected factors may also be removed, including amino acids, micronutrients, phosphorus, beneficial proteins, and even analytes used for diagnostic ...

This session provides a comprehensive update on dysnatremias, moving beyond traditional physiology to evidence-based practice. Experts debate the utility of the "DDAVP (desmopressin) clamp" strategy, present new paradigms for diagnosing diabetes insipidus (arginine vasopressin [AVP] deficiency) using copeptin, evaluate effective th...

Frailty is common among adults with CKD and is associated with increased morbidity and mortality. Assessment and management of frailty in patients with CKD require a multidisciplinary approach, with important implications for care planning. This session discusses measures and management of frailty and interventions to address it, a...

Heart failure with preserved ejection fraction (HFpEF) has emerged as a major contributor to the global heart failure burden. The rising prevalence of diabetes, hypertension, obesity, and an aging population has significantly increased the incidence of HFpEF. This session offers a structured overview of HFpEF, highlighting its chan...

The pathogenesis of kidney stones is multifactorial. Thus, a multidisciplinary team is needed to assess underlying biochemical and genetic risk factors, understand behavioral and environmental contributions, and design an individualized treatment strategy. Access to skilled urologic care is also essential for symptomatic, large, or...

This session reviews thrombotic microangiopathy (TMA), including its anatomic pathology, and distinguishes between renal-limited and systemic TMA. Experts discuss the modern classification of TMA and the latest updates on complement inhibition for the management of TMA and drug-induced TMA.

High-Impact Clinical Trials - 1 Note: Continuing education credits are not being offered for this session.

Delayed graft function (DGF) remains a frequent complication after kidney transplantation. Its duration and severity correlate with downstream outcomes, yet the heterogeneity of DGF creates uncertainty in prognostication and postdischarge care. This session summarizes the data and defines clinically meaningful DGF.

There is growing interest in making dialysis care more individualized, moving away from a one-size-fits-all approach. This session proposes strategies for achieving more personalized care that better aligns with the characteristics, risk factors, and goals of patients receiving maintenance dialysis.

The FIT Bowl will take place in the Futures Theater in the Exhibit Hall. Note: Continuing education credits are not being offered for this activity.

Comprehensive care for patients receiving dialysis extends beyond adequate dialysis and pharmacologic interventions. This session focuses on nutrition, cognition, and physical conditioning as key components of dialysis care. The session also examines the management of common symptoms experienced by people on dialysis.

This annual session, now in its ninth year, highlights innovative clinical, translational, and basic research in nephrology and presents diverse, novel, and clinically applicable science across multiple nephrology disciplines. High-impact articles published in JASN, CJASN, and Kidney360 in 2026 are presented by the journal editors.

Advancing the current management of kidney diseases and their secondary organ complications requires clarifying the kidneys' role in multiorgan interactions. This session moves beyond organ-specific silos to explore the complex signaling networks that connect organ systems, including the kidneys, brain, heart, and lungs. By integra...

Cellular therapies are rapidly reshaping the treatment landscape for autoimmune kidney diseases. This session explores emerging data on chimeric antigen receptor T-cell therapy (CAR-T), bispecific T-cell engagers, and related immune-reprogramming strategies; highlights mechanisms, early clinical experience, and safety consideration...

Despite recent breakthroughs in the field of podocytopathies, the mechanisms of podocyte injury remain incompletely understood. Most studies focus on podocyte biology; however, there is growing evidence of the endothelium's role in these conditions. Understanding the mechanisms by which the endothelium may alter podocyte health off...

This session discusses advances in our understanding of how changes in genetic material (e.g., chromosomes, DNA, RNA) can influence the development of CKD. The session highlights recent insights from the genetic mapping of declining kidney function. The effects of loss of genetic information, regulatory processing, and organelle dy...

Clarity is elusive as hypertension treatment for patients with CKD evolves amid new guidelines, devices, and clinical trial data. In this interactive debate session, internationally recognized experts tackle the most pressing controversies: how aggressively to lower blood pressure in CKD, whether and when to adopt renal denervation...

Diabetic kidney disease (DKD) has long been viewed primarily as a metabolic disorder with secondary inflammation. Recent advances now establish immune activation as a driver of disease progression. This session examines how adaptive and innate immune mechanisms contribute to DKD, focusing on T-cell recruitment and phenotypic states...

This session presents new data on the pathophysiology of aging kidneys across diverse cellular microenvironments, including cellular senescence, epigenetic changes, tertiary lymphoid structures, and DNA repair responses. The session also discusses how aging kidneys influence injury responses.

CKD-MBD pathogenesis is poorly understood. This session covers recent discoveries about the regulation of phosphate metabolism and fibroblast growth factor 23 (FGF-23) production, and their effects on CKD-MBD outcomes.

This session explores how advances in kidney transport physiology have driven progress in nephrology. Experts review proximal tubule transport mechanisms, including strategies to target sodium handling to overcome diuretic resistance, insights into glucose transport and uremic toxin formation, calcium vs. magnesium absorption via c...

Artificial intelligence (AI) and large-scale data resources are increasingly shaping pediatric nephrology research, offering new opportunities to study rare diseases, predict outcomes, and personalize care. This session introduces current pediatric nephrology studies that leverage AI and big data; reviews common data sources and an...

This session focuses on glomerular diseases in the kidney transplant setting, including clinicopathologic features and treatment of recurrent glomerular diseases. The session also provides updates on transplant glomerulopathy and glomerulitis and discusses thrombotic microangiopathy in the kidney transplant setting.

The US Centers for Medicare and Medicaid Services (CMS) sunset the Kidney Care First program, while continuing the Comprehensive Kidney Care Contracting (CKCC) model, albeit with major changes. More than 55% of Medicare-eligible beneficiaries are enrolled in Medicare Advantage, and many are enrolled in value-based care (VBC) progra...

This session explores recent advances in urinary biomarkers and their expanding role in diagnosing, monitoring, and predicting kidney diseases. Experts highlight cutting-edge research, discuss its clinical utility across acute and chronic kidney conditions, and examine how novel biomarker panels may support personalized treatment s...

This session highlights key challenges in kidney transplantation driven by the complexity of genetic and immune-mediated diseases. Topics include genotype-phenotype mismatch in transplant candidates, practical applications of genetic testing, and evaluation of living related donors when variants of uncertain significance are identi...

Progress in pediatric CKD is limited by small patient populations, fragmented trial infrastructure, and uncertainty about meaningful end points. This session highlights strategies to advance the field by centering patient and family engagement, leveraging pediatric trial networks, and grounding surrogate end points in biological pl...

Point-of-care ultrasonography (POCUS) is becoming an essential extension of the physical examination, yet limited training and overconfidence can lead to misinterpretation and patient harm. This expert-led session uses real-world nephrology case studies to illustrate practical POCUS applications, emphasizing accurate interpretation...

This session reviews the latest developments in amyloidosis that affect the kidneys. It starts with a review of the pathological features of renal amyloidosis, followed by a discussion of the necessary evaluation for patients suspected of having or diagnosed with amyloidosis. The latest treatments for light-chain amyloidosis (AL am...

Oral abstract sessions will be posted on October 2. Note: Continuing education credits are not being offered for these sessions.

Although new therapies for CKD associated with type 2 diabetes have emerged, many cannot be used by patients with type 1 diabetes. However, new clinical trials are assessing the efficacy and safety of novel interventions for CKD in patients with type 1 diabetes. This session reviews pathophysiological differences and similarities o...